{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:05:44Z","timestamp":1781247944328,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.urolonc.2025.08.028","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:58:55Z","timestamp":1758949135000},"page":"695.e1-695.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A randomized prospective trial comparing Bacillus Calmette-Gu\u00e9rin (BCG) RIVM and Russian strains in non-muscle invasive bladder cancer: Efficacy and side effects"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0580-1179","authenticated-orcid":false,"given":"Khaled","family":"Obaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7a\u011fr\u0131","family":"Akp\u0131nar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat Can","family":"Karaburun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Arif","family":"\u0130bi\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7a\u011fatay","family":"G\u00f6\u011f\u00fc\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir","family":"T\u00fcrk\u00f6lmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcmer","family":"Baltac\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evren","family":"S\u00fcer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.urolonc.2025.08.028_bib0001","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00428-015-1739-2","article-title":"Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old","volume":"466","author":"Comp\u00e9rat","year":"2015","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.028_bib0002","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.028_bib0003","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.08.028_bib0004","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.urolonc.2025.08.028_bib0005","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.028_bib0006","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JOP.2011.000480","article-title":"Adjuvant intravesical bacillus Calmette-Gu\u00e9rin therapy and survival among elderly patients with non-muscle-invasive bladder cancer","volume":"9","author":"Spencer","year":"2013","journal-title":"J Oncol Pract"},{"issue":"6","key":"10.1016\/j.urolonc.2025.08.028_bib0007","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.028_bib0008","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2006.06706.x","article-title":"Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus calmette-gu\u00e9rin in patients with high-risk bladder cancer","volume":"99","author":"G\u00e5rdmark","year":"2007","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.urolonc.2025.08.028_bib0009","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of Bacille Calmette-Gu\u00e9rin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.urolonc.2025.08.028_bib0010","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.urolonc.2025.08.028_bib0011","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41585-020-0346-4","article-title":"Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer","volume":"17","author":"van Puffelen","year":"2020","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.028_bib0012","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.08.028_bib0013","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1473-3099(02)00182-2","article-title":"BCG\u2013different strains, different vaccines?","volume":"2","author":"Behr","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.urolonc.2025.08.028_bib0014","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrurol.2013.194","article-title":"BCG immunotherapy for bladder cancer\u2013the effects of substrain differences","volume":"10","author":"Gan","year":"2013","journal-title":"Nat Rev Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.08.028_bib0015","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1080\/03007995.2017.1326889","article-title":"Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis","volume":"33","author":"Huang","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.urolonc.2025.08.028_bib0016","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of bacillus Calmette-Gu\u00e9rin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.08.028_bib0017","doi-asserted-by":"crossref","first-page":"484.e19","DOI":"10.1016\/j.urolonc.2016.05.033","article-title":"The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer","volume":"34","author":"Witjes","year":"2016","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.028_bib0018","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.08.028_bib0019","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/2090598X.2021.1874628","article-title":"Assessment of the oncological outcomes of three different bacillus Calmette-Gu\u00e9rin strains in patients with high-grade T1 non-muscle-invasive bladder cancer","volume":"19","author":"Nowak","year":"2021","journal-title":"Arab J Urol"},{"key":"10.1016\/j.urolonc.2025.08.028_bib0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.urology.2021.08.008","article-title":"Does switching Bacillus Calmette-Guerin strains during maintenance therapy affect the outcome in non-muscle invasive bladder cancer?","volume":"158","author":"S\u00fcer","year":"2021","journal-title":"Urology"},{"issue":"10","key":"10.1016\/j.urolonc.2025.08.028_bib0021","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1007\/s00432-021-03571-0","article-title":"Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate\/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis","volume":"147","author":"Del Giudice","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2025.08.028_bib0022","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2169\/internalmedicine.56.8055","article-title":"Tuberculosis that developed after intravesical Bacillus Calmette-Guerin therapy","volume":"56","author":"Kaburaki","year":"2017","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.urolonc.2025.08.028_bib0023","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000492722","article-title":"Are there differences in toxicity and efficacy between various Bacillus Calmette-guerin strains in bladder cancer patients? Analysis of 844 patients","volume":"101","author":"Krajewski","year":"2018","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.urolonc.2025.08.028_bib0024","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.acuro.2017.10.003","article-title":"Safety and efficacy of various strains of bacille Calmette-Gu\u00e9rin in the treatment of bladder tumours in standard clinical practice","volume":"42","author":"Unda-Urzaiz","year":"2018","journal-title":"Actas Urol Esp (Engl Ed)"},{"issue":"6","key":"10.1016\/j.urolonc.2025.08.028_bib0025","doi-asserted-by":"crossref","first-page":"306.e1","DOI":"10.1016\/j.urolonc.2018.02.005","article-title":"Does switching the bacillus Calmette-Gu\u00e9rin strain affect clinical outcome in patients with recurrent non-muscle-invasive bladder cancer after initial bacillus Calmette-Gu\u00e9rin therapy?","volume":"36","author":"Niwa","year":"2018","journal-title":"Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T23:19:25Z","timestamp":1763680765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925003497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1078143925003497"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.028","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized prospective trial comparing Bacillus Calmette-Gu\u00e9rin (BCG) RIVM and Russian strains in non-muscle invasive bladder cancer: Efficacy and side effects","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}